Dimerix

Dimerix Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Dimerix (DXB.AX) as of Oct 11, 2026 is 173.78 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was -294.70 % — a change of -158.97% (higher).

Cash Conversion

173.78 %

YoY

-158.97%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Dimerix is 2026 173.78 % . Cash Conversion Rate (OCF/Net Income) of Dimerix was 2025 -294.70 % . It decreases by -158.97% higher compared to the previous year.

The Dimerix Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2019
95.32 AUD
Jan 1, 2020
105.06 AUD
Jan 1, 2021
101.42 AUD
Jan 1, 2022
128.07 AUD
Jan 1, 2023
92.23 AUD
Jan 1, 2024
41.02 AUD
Jan 1, 2025
-294.70 AUD
Jan 1, 2026
173.78 AUD
The Dimerix Cash Conversion history
YEARCash ConversionYoY
173.78 %-158.97%
-294.70 %-818.44%
41.02 %-55.53%
92.23 %-27.99%
128.07 %+26.27%
101.42 %-3.46%
105.06 %+10.23%
95.32 %-1.89%
97.15 %-8.34%
105.99 %+303.79%
26.25 %-68.04%
82.14 %-68.34%
259.45 %—
Access this data via the Eulerpool API

Dimerix Stock analysis

What does Dimerix do? Dimerix Ltd is an Australian biotechnology company specializing in the development of innovative therapies for various medical needs. Their business model is based on identifying new targets for drug development, often through collaborations with other biotech or pharmaceutical companies. Dimerix focuses on cancer therapy, utilizing their innovative platform technology to identify and test a variety of drug candidates. They also have a pipeline of medications for kidney and lung diseases, as well as inflammation and pain. Dimerix actively seeks partnerships with other companies and research institutions to bring innovative therapies to market. One of their key products, DMX-200, is currently in phase II clinical trials for the treatment of kidney diseases and has shown promising results. Overall, Dimerix is well-positioned to continue bringing successful therapies to market in the future. Dimerix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dimerix stock

Cash Conversion Rate (OCF/Net Income) of Dimerix is 173.78 % in 2026.

Cash Conversion Rate (OCF/Net Income) of Dimerix changed from -294.70 % to 173.78 %, representing a -158.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Dimerix since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Dimerix with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

Cash Flow — Dimerix

All Key Metrics — Dimerix